- Home
- RARE vs RYN Comparison
RARE vs RYN Comparison
Compare RARE & RYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- RYN
- Stock Information
- Founded
- RARE 2010
- RYN 1926
- Country
- RARE United States
- RYN United States
- Employees
- RARE N/A
- RYN N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- RYN Real Estate Investment Trusts
- Sector
- RARE Health Care
- RYN Real Estate
- Exchange
- RARE Nasdaq
- RYN Nasdaq
- Market Cap
- RARE 5.2B
- RYN 4.5B
- IPO Year
- RARE 2014
- RYN N/A
- Fundamental
- Price
- RARE $40.89
- RYN $26.73
- Analyst Decision
- RARE Strong Buy
- RYN Hold
- Analyst Count
- RARE 15
- RYN 3
- Target Price
- RARE $92.00
- RYN $33.00
- AVG Volume (30 Days)
- RARE 1.0M
- RYN 876.1K
- Earning Date
- RARE 02-13-2025
- RYN 02-05-2025
- Dividend Yield
- RARE N/A
- RYN 11.04%
- EPS Growth
- RARE N/A
- RYN 98.46
- EPS
- RARE N/A
- RYN 1.07
- Revenue
- RARE $522,745,000.00
- RYN $1,004,107,000.00
- Revenue This Year
- RARE $26.70
- RYN N/A
- Revenue Next Year
- RARE $19.02
- RYN N/A
- P/E Ratio
- RARE N/A
- RYN $24.95
- Revenue Growth
- RARE 27.44
- RYN 20.26
- 52 Week Low
- RARE $37.02
- RYN $24.88
- 52 Week High
- RARE $60.37
- RYN $35.29
- Technical
- Relative Strength Index (RSI)
- RARE 40.43
- RYN 46.83
- Support Level
- RARE $39.99
- RYN $24.88
- Resistance Level
- RARE $44.52
- RYN $26.62
- Average True Range (ATR)
- RARE 2.18
- RYN 0.59
- MACD
- RARE -0.03
- RYN 0.25
- Stochastic Oscillator
- RARE 17.75
- RYN 91.58
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.